Agios Pharmaceuticals, Inc. (AGIO) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGS. Market cap 1.91B USD. 52-week range 22.24 to 46.00 USD. Data as of 2026-10-09.
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in ...